TITLE

Reasons Why High Religiosity Can Co-exist with and Precipitate Discontinuation of Anti-retroviral Therapy among Different HIV Clients in Uganda: An Exploratory Study

AUTHOR(S)
Tumwine, Christopher; Neema, Stella; Wagner, Glenn
PUB. DATE
September 2012
SOURCE
Religions;Sep2012, Vol. 3 Issue 3, p817
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
In-depth interviews were conducted with 39 very religious people living with HIV (16 had ever and 23 had never discontinued antiretroviral therapy--ART) to assess the role of religion in these treatment decisions and in coping with HIV. Participants who had ever discontinued ART gave reasons such as: teachings and prophecies from religious leaders, and supporting Biblical scriptures all of which led them to feel that God and their faith, not ART, would help them; and testimonies by their "already healed" peers who had stopped ART. Participants who had never discontinued ART gave reasons such as continuous adherence counseling from multiple sources, improvement in physical health as a result of ART, and beliefs that God heals in different ways and that non-adherence is equal to putting God to a test. High religiosity was reported to help participants cope with HIV through engagement in personal and or community protective behaviours, "taking care of other illness", and reducing worries. When high religiosity among people living with HIV (PHAs) becomes a barrier to ART adherence, the adherence counseling provided can draw on experiences of PHAs with high religiosity who have sustained good adherence to ART and achieved good health outcomes.
ACCESSION #
82602690

 

Related Articles

  • A Description of Mortality Associated with IPT plus ART Compared to ART Alone among HIV-Infected Individuals in Addis Ababa, Ethiopia: A Cohort Study. Edessa, Dumessa; Likisa, Jimma // PLoS ONE;9/8/2015, Vol. 10 Issue 9, p1 

    Background: Tuberculosis (TB) is the most common human immunodeficiency virus (HIV) associated opportunistic infection. It is the leading cause of death in HIV-infected individuals in sub-Saharan Africa. Anti-retroviral therapy (ART) and isoniazid preventive therapy (IPT) are the two useful TB...

  • Age at Entry Into Care, Timing of Antiretroviral Therapy Initiation, and 10-Year Mortality Among HIV-Seropositive Adults in the United States. Edwards, Jessie K.; Cole, Stephen R.; Westreich, Daniel; Mugavero, Michael J.; Eron, Joseph J.; Moore, Richard D.; Mathews, William C.; Hunt, Peter; Williams, Carolyn // Clinical Infectious Diseases;10/1/2015, Vol. 61 Issue 7, p1189 

    Background. The goal of targeted antiretroviral therapy initiation is to minimize disease progression among patients with human immunodeficiency virus while minimizing the therapeutic burden on these patients. We examine whether the effect of delaying therapy initiation from 500 cells/mm³ to...

  • Use of first line antiretroviral therapy from a free ART programme clinic in Pune, India - A preliminary report. Ghate, Manisha; Tripathy, Srikanth; Gangakhedkar, Raman; Thakar, Madhuri; Bhattacharya, Jayanta; Choudhury, Ipsita; Risbud, Arun; Bembalkar, Shilpa; Kadam, Dileep; Rewari, Bharat B.; Paranjape, Ramesh // Indian Journal of Medical Research;May2013, Vol. 137 Issue 5, p942 

    Background & objectives: The treatment outcomes under national antiretroviral therapy (ART) programme are being evaluated in some ART centres in the country. We carried out this study to analyze the impact of first line antiretroviral therapy in HIV infected patients attending a free ART roll...

  • Efficacy, safety and pharmacokinetics of 900/100 mg of darunavir/ritonavir once daily in treatment-experienced patients. Curran, Adrian; Gutirerrez, Mar; Deig, Elisabet; Mateo, Gracia; Lopez, Rosa Maria; Imaz, Arkaitz; Crespo, Manuel; Ocaña, Inma; Domingo, Pere; Ribera, Esteban // Journal of Antimicrobial Chemotherapy (JAC);Oct2010, Vol. 65 Issue 10, p2195 

    Objectives: To evaluate the virological efficacy, safety, tolerability and pharmacokinetics of a regimen containing 900/100 mg of ritonavir-boosted darunavir once daily in patients with antiretroviral experience but no darunavir resistance.

  • IL-2 therapy: potential impact of the CD4 cell count at initiation on clinical efficacy—results from the ANRS CO4 cohort. Fontas, Eric; Kousignian, Isabelle; Pradier, Christian; Poizot-Martin, Isabelle; Durier, Christine; Weiss, Laurence; Levy, Yves; Costagliola, Dominique // Journal of Antimicrobial Chemotherapy (JAC);Oct2010, Vol. 65 Issue 10, p2215 

    Objectives: We investigated why, despite its beneficial effect on the CD4 cell count, IL-2 therapy had no clinical benefit as shown in the ESPRIT and SILCAAT trials. We focused on subgroups of patients defined according to CD4 cell counts at baseline and over time to assess the threshold above...

  • Immunologic response among HIV-infected patients enrolled in a graduated cost-recovery programme of antiretroviral therapy delivery in Chennai, India. Solomon, Sunil Suhas; Ganesh, Aylur K.; Mehta, Shruti H.; Yepthomi, Tokugha; Balaji, Kavitha; Anand, Santhanam; Gallant, Joel E.; Solomon, Suniti // Indian Journal of Medical Research;Jun2013, Vol. 137 Issue 6, p1145 

    Background & objectives: Sustainability of free antiretroviral therapy (ART) roll out programmes in resource-limited settings is challenging given the need for lifelong therapy and lack of effective vaccine. This study was undertaken to compare treatment outcomes among HIV-infected patients...

  • Outcomes of second-line combination antiretroviral therapy for HIV-infected patients: a cohort study from Rio de Janeiro, Brazil. Cardoso, Sandra Wagner; Luz, Paula Mendes; Velasque, Luciane; Torres, Thiago S.; Tavares, Isabel C.; Ribeiro, Sayonara Rocha; Moreira, Ronaldo Ismério; Veloso, Valdilea Gonçalves; Moore, Richard D.; Grinsztejn, Beatriz // BMC Infectious Diseases;2014, Vol. 14 Issue 1, p780 

    Background World-wide, the notable expansion of HIV/AIDS treatment programs in resource-limited settings has lead to an increasing number of patients in need of second-line cART. To adequately address and prepare for this scenario, critical assessments of the outcomes of second-line cART are...

  • Impact of Risk Factors for Specific Causes of Death in the First and Subsequent Years of Antiretroviral Therapy Among HIV-Infected Patients. Ingle, Suzanne M.; May, Margaret T.; Gill, M. John; Mugavero, Michael J.; Lewden, Charlotte; Abgrall, Sophie; Fätkenheuer, Gerd; Reiss, Peter; Saag, Michael S.; Manzardo, Christian; Grabar, Sophie; Bruyand, Mathias; Moore, David; Mocroft, Amanda; Sterling, Timothy R.; D'Arminio Monforte, Antonella; Hernando, Victoria; Teira, Ramon; Guest, Jodie; Cavassini, Matthias // Clinical Infectious Diseases;Jul2014, Vol. 59 Issue 2, p287 

    Among HIV-infected patients who initiated antiretroviral therapy (ART), patterns of cause-specific death varied by ART duration and were strongly related to age, sex, and transmission risk group. Deaths from non-AIDS malignancies were much more frequent than those from cardiovascular...

  • Global patient safety and antiretroviral drug–drug interactions in the resource-limited setting. Seden, Kay; Khoo, Saye H.; Back, David; Byakika-Kibwika, Pauline; Lamorde, Mohammed; Ryan, Mairin; Merry, Concepta // Journal of Antimicrobial Chemotherapy (JAC);Jan2013, Vol. 68 Issue 1, p1 

    Scale-up of HIV treatment services may have contributed to an increase in functional health facilities available in resource-limited settings and an increase in patient use of facilities and retention in care. As more patients are reached with medicines, monitoring patient safety is increasingly...

Share

Read the Article

Courtesy of NEW JERSEY STATE LIBRARY

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics